Top

International Journal of Clinical Oncology

Published in:

01-08-2016 | Original Article

Clinical outcomes of abnormal cervical cytology and human papillomavirus-related lesions in patients with organ transplantation: 11-year experience at a single institution

Authors: Yusuke Tanaka, Yutaka Ueda, Mamoru Kakuda, Satoshi Kubota, Satoko Matsuzaki, Satoshi Nakagawa, Tomomi Egawa-Takata, Shinya Matsuzaki, Eiji Kobayashi, Kiyoshi Yoshino, Tadashi Kimura

Published in: International Journal of Clinical Oncology | Issue 4/2016

Abstract

Objectives

The objective of this study is to analyze the clinical outcomes of abnormal cervical cytology and newly diagnosed human papillomavirus (HPV)-related disease after organ transplantation.

Materials and methods

Medical records from July 2004 to August 2015 were reviewed, and thirteen patients were identified who had been newly diagnosed with HPV-related disease (cervical intraepithelial neoplasia [CIN] and cervical cancer) after organ transplantation. The median transition time to the aggravation of cervical cytology and the spontaneous regression rate of CIN were evaluated. Clinical outcomes of CIN1 and CIN2 were compared between the general population and patients with organ transplantation. We also reviewed the current literature regarding the incidence of HPV infection, Pap smear abnormality and/or CIN after organ transplantation.

Results

The cervical cytology aggravated in nine of the 13 patients (69 %). In seven of the 13 cases (54 %), treatments such as cervical conization, laser vaporization, or radiation therapy, were conducted. HPV-related disease disappeared after treatment in only three of the seven actively treated cases (43 %). In contrast, the lesions persisted in three (43 %) cases after treatment. One patient died from cervical cancer. The spontaneous regression rate of the HPV-related diseases, if left untreated, was 0 %. There was a statistically significant difference in the clinical outcomes of CIN1 and CIN2 between the general population and patients with organ transplantation (p = 0.0026 and 0.0315, respectively; chi-squared test).

Conclusions

HPV-related lesions that are newly diagnosed after organ transplantation do not seem to regress as spontaneously as in the general population. Physicians should recognize the importance of close monitoring and long-term follow-up.

Girardi F, Reich O, Tamussino K (2015) Human papillomaviruses and cervical cancer. In: Girardi F, Reich O, Tamussino K (eds) Burghardt’s colposcopy and cervical pathology: textbook and atlas, 4th edn. Thieme, Stuttgart, pp 10–22

Committee on Practice Bulletins-Gynecology (2012) ACOG practice bulletin number 131: screening for cervical cancer. Obstet Gynecol 120:1222–1238

Japan Society of Obstetrics and Gynecology and Japan Association of Obstetricians and Gynecologists. Guidelines for gynecological practice in Japan. 2014. (In Japanese)

Ueda Y, Enomoto T, Miyatake T et al (2003) Monoclonal expansion with integration of high-risk type human papillomaviruses is an initial step for cervical carcinogenesis: association of clonal status and human papillomavirus infection with clinical outcome in cervical intraepithelial neoplasia. Lab Invest 83:1517–1527CrossRefPubMed

Veroux M, Corona D, Scalia G et al (2009) Surveillance of human papilloma virus infection and cervical cancer in kidney transplant recipients: preliminary data. Transplant Proc 41:1191–1194CrossRefPubMed

Wang Y, Brinch L, Jebsen P et al (2012) A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation. Biol Blood Marrow Transplant 18:747–753CrossRefPubMed

Mazanowska N, Pietrzak B, Kamiński P et al (2013) Prevalence of cervical high-risk human papillomavirus infections in kidney graft recipients. Ann Transplant 18:656–660CrossRefPubMed

Pietrzak B, Mazanowska N, Ekiel AM et al (2012) Prevalence of high-risk human papillomavirus cervical infection in female kidney graft recipients: an observational study. Virol J 9:117CrossRefPubMedPubMedCentral

Origoni M, Stefani C, Dell’Antonio G et al (2011) Cervical Human Papillomavirus in transplanted Italian women: a long-term prospective follow-up study. J Clin Virol 51:250–254CrossRefPubMed

10.

Paternoster DM, Cester M, Resente C et al (2008) Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 40:1877–1880CrossRefPubMed

11.

Savani BN, Stratton P, Shenoy A et al (2008) Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation–implications for screening and HPV vaccination. Biol Blood Marrow Transplant 14:1072–1075CrossRefPubMedPubMedCentral

12.

Courtney AE, Leonard N, O’Neill CJ et al (2009) The uptake of cervical cancer screening by renal transplant recipients. Nephrol Dial Transplant 24:647–652CrossRefPubMed

13.

Ghazizadeh S, Lessan-Pezeshki M, Nahayati MA (2011) Human papilloma virus infection in female kidney transplant recipients. Saudi J Kidney Dis Transpl 22:433–436PubMed

14.

Aggarwal R, Suri V, Awasthi S et al (2014) Prevalence and genotypes of HPV in female renal transplant recipients in North India. Int J Gynecol Pathol 33:537–542CrossRefPubMed

15.

Creasman WT (2007) Preinvasive disease of the cervix. In: Di Saia PJ, Creasman WT (eds) Clinical gynecologic oncology, 8th edn. Elsevier, Philadelphia, pp 1–36CrossRef

16.

Meeuwis KA, Hilbrands LB, IntHout J et al (2015) Cervicovaginal HPV infection in female renal transplant recipients: an observational, self-sampling based, cohort study. Am J Transplant 15:723–733CrossRefPubMed

17.

Strickler HD, Palefsky JM, Shah KV et al (2003) Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 95:1062–1071CrossRefPubMed

18.

Ostör AG (1993) Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12:186–192CrossRefPubMed

19.

Moore K, Cofer A, Elliot L et al (2007) Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol 197:141 (e1-6) PubMed

20.

McAllum B, Sykes PH, Sadler L et al (2011) Is the treatment of CIN 2 always necessary in women under 25 years old? Am J Obstet Gynecol 205:478 (e1-7) CrossRefPubMed

Title: Clinical outcomes of abnormal cervical cytology and human papillomavirus-related lesions in patients with organ transplantation: 11-year experience at a single institution
Authors: Yusuke Tanaka
Yutaka Ueda
Mamoru Kakuda
Satoshi Kubota
Satoko Matsuzaki
Satoshi Nakagawa
Tomomi Egawa-Takata
Shinya Matsuzaki
Eiji Kobayashi
Kiyoshi Yoshino
Tadashi Kimura
Publication date: 01-08-2016
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0940-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2016

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan

Biological imaging in clinical oncology: radiation therapy based on functional imaging

Tumor hypoxia: a new PET imaging biomarker in clinical oncology

Perspectives of Japanese oncologists on the health economics of innovative cancer treatments

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer